Jubilant Pharmova Ltd - 530019 - Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to manufacturing partnership for US production of COVID-19 Vaccine candidate, COVAXIN(r) by Jubilant HollisterStier LLC, a step down subsidiary of the Company. Jubilant Pharmova Ltd - 530019 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report dated June 4, 2021 for the financial year 2020-21. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising Investor and Analyst Meet on June 18, 2021. Details of the same are attached. This is for information and record.
Buy Jubilant Pharmova; target of Rs 1000: ICICI Direct
ICICI Direct is bullish on Jubilant Pharmova recommended buy rating on the stock with a target price of Rs 1000 in its research report dated June 06, 2021. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated June 4, 2021, we enclose copies of the Audited Consolidated Financial Results for the quarter and year ended March 31, 2021 published on June 5, 2021 in MINT (English) and HINDUSTAN (Hindi).
Jubilant Pharmova reports net profit of Rs 214 crore in Q4; FY21 profit at Rs 836 crore
The drug firm said it plans to incur a capital expenditure of Rs 700-800 crore in the current fiscal on the addition of a new high speed fill and finish line with lyophilizer at Spokane site (US) and expansion of CRDS (Contract Research and Development Services) capacity.
Earnings Call for Q4FY21 of Jubilant Pharmova
Conference Call with Jubilant Pharmova Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Dividend Updates
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on June 4, 2021, recommended a dividend of Rs. 5 (Rupees five only) per equity share of Re.1 each for the year ended March 31, 2021. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / despatched on or before October 20, 2021. We request you to take the same on record. Jubilant Pharmova Ltd - 530019 - Results For The Quarter And Year Ended March 31, 2021
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021 were approved by the Board of Directors of the Company at its meeting held today at 1:35 p.m. and concluded at 4.20 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2021; 2. Audit Reports for Standalone and Consolidated Financial Results; 3. Copies of the Press Release and Presentation. We declare that the Reports of Auditors are with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021.